Generic drug sector seeks policy fixes after Trump tariff threat

• Tariffs on imported generic drugs will remain at 0% for two years starting August 1, then jump to 100% for one year, and eventually reach 200%
• The Association for Accessible Medicines says the industry has grown significantly over the past two years but still faces structural purchasing and reimbursement problems that limit growth
• Patient advocacy groups warn the tariffs could make lower-cost generic drugs that millions rely on more expensive and harder to access

Summary

President Donald Trump announced a phased tariff plan on imported generic drugs, starting August 1 with a 0% rate for two years, escalating to 100% in year three, and reaching 200% thereafter. The announcement has triggered concerns across the pharmaceutical industry about drug affordability and access.

Key Industry Response:

John Murphy III, CEO of the Association for Accessible Medicines, acknowledged significant U.S. industry growth over the past two years through supply chain investments, but emphasized that structural problems in purchasing and reimbursement systems remain major growth inhibitors. The industry is seeking legislative and regulatory solutions and plans dialogue with the administration and Congress.

Market Implications:

Patient advocacy groups warn the tariffs could make lower-cost generic medications—relied upon by millions of Americans—significantly more expensive and harder to access. This poses a direct threat to healthcare affordability in the U.S. market.

Companies Affected:

Major generic drug suppliers to the U.S. market, including Indian pharmaceutical manufacturers and Sandoz, have been mentioned as key stakeholders. Sandoz indicated it would continue discussions with policymakers regarding the tariff implementation.

Timeline:

• August 1: Tariff implementation begins at 0%
• Years 1-2: 0% tariff rate
• Year 3: 100% tariff rate
• Year 4+: 200% tariff rate

The generic drug sector faces a two-year window to address structural market issues and advocate for policy changes before potentially facing severe cost pressures that could ripple through to consumers and healthcare systems.